Free Trial

Heron Therapeutics (HRTX) Competitors

Heron Therapeutics logo
$1.69 -0.04 (-2.31%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$1.68 -0.01 (-0.83%)
As of 08/1/2025 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

HRTX vs. PRAX, MENS, SANA, DYN, AMPH, AVDL, GPCR, PHVS, RCUS, and ARDX

Should you be buying Heron Therapeutics stock or one of its competitors? The main competitors of Heron Therapeutics include Praxis Precision Medicines (PRAX), Jyong Biotech (MENS), Sana Biotechnology (SANA), Dyne Therapeutics (DYN), Amphastar Pharmaceuticals (AMPH), Avadel Pharmaceuticals (AVDL), Structure Therapeutics (GPCR), Pharvaris (PHVS), Arcus Biosciences (RCUS), and Ardelyx (ARDX). These companies are all part of the "pharmaceutical products" industry.

Heron Therapeutics vs. Its Competitors

Heron Therapeutics (NASDAQ:HRTX) and Praxis Precision Medicines (NASDAQ:PRAX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, dividends, media sentiment and valuation.

In the previous week, Praxis Precision Medicines had 2 more articles in the media than Heron Therapeutics. MarketBeat recorded 5 mentions for Praxis Precision Medicines and 3 mentions for Heron Therapeutics. Praxis Precision Medicines' average media sentiment score of 0.67 beat Heron Therapeutics' score of 0.64 indicating that Praxis Precision Medicines is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Heron Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Praxis Precision Medicines
2 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Heron Therapeutics has a beta of 1.18, indicating that its stock price is 18% more volatile than the S&P 500. Comparatively, Praxis Precision Medicines has a beta of 2.62, indicating that its stock price is 162% more volatile than the S&P 500.

80.0% of Heron Therapeutics shares are owned by institutional investors. Comparatively, 67.8% of Praxis Precision Medicines shares are owned by institutional investors. 5.9% of Heron Therapeutics shares are owned by company insiders. Comparatively, 2.7% of Praxis Precision Medicines shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Heron Therapeutics currently has a consensus target price of $5.00, indicating a potential upside of 195.86%. Praxis Precision Medicines has a consensus target price of $94.11, indicating a potential upside of 73.99%. Given Heron Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Heron Therapeutics is more favorable than Praxis Precision Medicines.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Heron Therapeutics
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
Praxis Precision Medicines
1 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.78

Heron Therapeutics has higher revenue and earnings than Praxis Precision Medicines. Heron Therapeutics is trading at a lower price-to-earnings ratio than Praxis Precision Medicines, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Heron Therapeutics$148.52M1.74-$13.58M-$0.06-28.17
Praxis Precision Medicines$8.55M128.87-$182.82M-$10.72-5.05

Heron Therapeutics has a net margin of -5.24% compared to Praxis Precision Medicines' net margin of -2,137.48%. Heron Therapeutics' return on equity of 0.00% beat Praxis Precision Medicines' return on equity.

Company Net Margins Return on Equity Return on Assets
Heron Therapeutics-5.24% N/A -3.43%
Praxis Precision Medicines -2,137.48%-50.42%-46.74%

Summary

Heron Therapeutics beats Praxis Precision Medicines on 10 of the 16 factors compared between the two stocks.

Get Heron Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for HRTX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

HRTX vs. The Competition

MetricHeron TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$263.94M$2.47B$5.47B$9.53B
Dividend YieldN/A1.81%4.74%4.08%
P/E Ratio-28.178.9728.6723.80
Price / Sales1.74639.67422.3188.12
Price / CashN/A157.7635.4557.96
Price / Book-7.684.838.275.55
Net Income-$13.58M$31.62M$3.24B$259.03M
7 Day Performance-11.52%-5.28%-3.63%-4.56%
1 Month Performance-21.40%4.38%4.40%4.49%
1 Year Performance-37.75%-2.49%25.97%18.05%

Heron Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HRTX
Heron Therapeutics
3.7112 of 5 stars
$1.69
-2.3%
$5.00
+195.9%
-39.9%$263.94M$148.52M-28.17300
PRAX
Praxis Precision Medicines
2.4074 of 5 stars
$55.65
-6.0%
$94.11
+69.1%
-5.0%$1.13B$8.55M-5.19110Analyst Forecast
MENS
Jyong Biotech
N/A$14.48
+4.9%
N/AN/A$1.10BN/A0.0031Positive News
Quiet Period Expiration
SANA
Sana Biotechnology
3.1569 of 5 stars
$4.88
-1.4%
$9.17
+87.8%
-27.1%$1.10BN/A-5.55380News Coverage
Upcoming Earnings
Gap Down
DYN
Dyne Therapeutics
3.572 of 5 stars
$9.31
-6.4%
$40.63
+336.4%
-76.1%$1.06BN/A-2.59100Trending News
Earnings Report
Analyst Forecast
Analyst Revision
AMPH
Amphastar Pharmaceuticals
4.377 of 5 stars
$22.24
-0.6%
$32.33
+45.4%
-50.0%$1.05B$730.66M8.062,028News Coverage
Upcoming Earnings
AVDL
Avadel Pharmaceuticals
2.6701 of 5 stars
$10.83
-1.8%
$18.33
+69.3%
-32.9%$1.05B$169.12M-40.1170News Coverage
Upcoming Earnings
GPCR
Structure Therapeutics
2.0331 of 5 stars
$18.27
+1.8%
$76.17
+316.9%
-51.7%$1.05BN/A-21.00136News Coverage
Positive News
Upcoming Earnings
PHVS
Pharvaris
1.706 of 5 stars
$20.00
-3.0%
$36.20
+81.0%
+25.5%$1.05BN/A-6.6430
RCUS
Arcus Biosciences
2.1329 of 5 stars
$9.85
-3.7%
$21.29
+116.1%
-41.8%$1.04B$258M-2.35500Upcoming Earnings
ARDX
Ardelyx
4.1303 of 5 stars
$4.28
-0.2%
$10.89
+154.4%
-21.3%$1.02B$361.71M-19.4590News Coverage
Upcoming Earnings

Related Companies and Tools


This page (NASDAQ:HRTX) was last updated on 8/2/2025 by MarketBeat.com Staff
From Our Partners